Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

RayzeBio, Inc. - Common Stock (NQ: RYZB )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about RayzeBio, Inc. - Common Stock

< Previous 1 2 Next >
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer... 
Via Benzinga
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
From Bristol Myers Squibb
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)
From Brodsky & Smith LLC
Via GlobeNewswire
Health Care Company Bristol-Myers Squibb Announces Merger With RayzeBio
Via Benzinga
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
From Bristol Myers Squibb
Via Business Wire
Pancreatic Cancer Treatments Poised for Major Advances in 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
The Best-Performing U.S. IPOs Of 2023
In 2023, there were 154 IPOs on the U.S. stock market. Here is a look at some of the best initial public offerings from last year. 
Via Talk Markets
IPO watch 2024: Which new stocks will hit the market?
Expectations are high for the 2024 IPO market, with Reddit, Databricks, and Shein debuts anticipated, hinting at a substantial influx of new public companies. 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
Cramer Says This 'Inexpensive' Stock Is 'Doing Some Great Things With Aerospace'
Jim Cramer said WK Kellogg Co (NYSE: KLG) doesn’t have a "lot of growth, and it doesn’t have a lot of yield." He prefers Kellanova (NYSE: K) 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
From Brodsky & Smith LLC
Via GlobeNewswire
RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB
From Kahn Swick & Foti, LLC
Via Business Wire
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. 
Via MarketBeat
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
The major indexes boast big annual gains with the Dow at record highs. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole... 
Via Benzinga
Investor Sentiment Improves; Dow Jumps Over 150 Points
The CNN Money Fear and Greed index showed an increase in overall market sentiment, while the index remained in the "Extreme Greed" zone on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
From Brodsky & Smith LLC
Via GlobeNewswire
Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Stocks Extend Gains As Oil Prices Rise
The short sprint to the end of 2023 is off to a good start, with the Dow Jones Industrial Average, S&P 500 Index, and Nasdaq Composite all sporting solid gains this afternoon. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%
Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower. 
Via Investor's Business Daily
Why Is RayzeBio (RYZB) Stock Up 100% Today?
RYZB stock has doubled today after Bristol Myers Squibb shelled out $4.1 billion to buy RayzeBio. Expect more such deals in 2024. 
Via InvestorPlace
RYZB Stock Alert: Halper Sadeh LLC Is Investigating RayzeBio, Inc.
From Halper Sadeh LLC
Via Business Wire
Bristol Myers Squibb Takes On Novartis, Eli Lilly With RayzeBio $4B Deal In Radiopharmaceuticals
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of < 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
From Rayzebio, Inc.
Via GlobeNewswire
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
From Bristol Myers Squibb
Via Business Wire
RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Rayzebio, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.